Organization: NeuroMed Technologies Inc

NeuroMed takes top spot with US$32M financing round

NeuroMed Technologies Inc has scored the largest private biotech financing in Canada this year, raising US$32 million for development of its next-generation chronic pain drugs. Proceeds will be used to move the Vancouver-based company’s lead compound to completion of Phase II clinical trials, and to fund further development of its preclinical pipeline. Investors in the…

NeuroMed raises $17 million to further clinical trials

NeuroMed Technologies Inc, Vancouver, has bucked the cooling trend in biotechnology financing raised $17 million to take its pain compounds up to the beginning of Phase II clinical trials. Its R&D into neur-onal calcium blockers aims to develop alternative painkillers to morphine and neuroprotective drugs for stroke. The second-round private financing was provided by GrowthWorks…